Sarepta Therapeutics, Inc.
SRPT
Updated: 23/09/2026, 19:08:41
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
No summaries found.
- Share price
- $19.41
- Market cap
- $2.05B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Michael E. Severino
- Employees
- 835
- IPO date
- 04/06/1997
- Beta
- 0.205
- Last dividend
- $0.00
- Day range
- $19.24 – $20.76
- 52-week range
- $14.68 – $25.32
- 1-day performance
- -6.71%
- 1-year performance
- 32.25%
- Current drawdown (1Y)
- -23.33%
- CIK
- 0000873303
- CUSIP
- 803607100
- ISIN
- US8036071004
- Created
- 07/12/2025, 14:23:06
- Last update
- 23/09/2026, 19:08:41
Track Sarepta Therapeutics, Inc. with an AI analyst
See which prediction-market events move SRPT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 16:48:30
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
Zacks Investment Research • STOCK • 08/06/2026, 15:01:05
SRPT vs. ARGX: Which Stock Is the Better Value Option?
Zacks Investment Research • STOCK • 08/06/2026, 14:41:08
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Seeking Alpha • STOCK • 04/06/2026, 13:41:54
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
Business Wire • STOCK • 01/06/2026, 18:30:00
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
Zacks Investment Research • STOCK • 07/05/2026, 13:51:10
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 01:41:15
SRPT Stock Surges on Promising Early Results From siRNA Programs
Zacks Investment Research • STOCK • 26/03/2026, 15:15:33
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Zacks Investment Research • STOCK • 26/03/2026, 11:01:25
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Seeking Alpha • STOCK • 25/03/2026, 18:35:55
Sarepta Therapeutics' experimental siRNA therapies show promising early results
Proactive Investors • STOCK • 25/03/2026, 12:39:05
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
24/7 Wall Street • STOCK • 25/03/2026, 10:44:47